No Data
No Data
RBC Capital Maintains Johnson & Johnson(JNJ.US) With Buy Rating, Maintains Target Price $181
Goldman Sachs Adjusts Price Target on Johnson & Johnson to $176 From $172, Maintains Buy Rating
SA Charts: How U.S. Manufacturing Jobs Have Declined Since the 1980s
Express News | Jnj-Backed Histosonics Is Pursuing a Sale After Fielding Takeover Bids, Seeking a Valuation of More Than $2.5Bn - FT
8 Health Care Stocks Whale Activity In Today's Session
Johnson & Johnson (JNJ.US) has received FDA approval for a potential blockbuster therapy.
Zhitong Finance APP learned that Johnson & Johnson (JNJ.US) announced that the USA FDA has approved the market launch of its antibody therapy Imaavy (nipocalimab).
loading...